Details
Zusammenfassung: <jats:title>ABSTRACT</jats:title> <jats:p> A negative extended-spectrum β-lactamase (ESBL) confirmation test result obtained after a positive ESBL screening test result using Clinical and Laboratory Standards Institute methods has been a common occurrence among isolates of <jats:italic>Escherichia coli</jats:italic> and <jats:italic>Klebsiella pneumoniae</jats:italic> in the SENTRY Antimicrobial Surveillance Program in the Asia-Pacific region. Among isolates collected between 1998 and 2004 this screen-positive, nonconfirmed profile (failed to show clavulanate synergy) was observed in 8.9% of 4,515 <jats:italic>E. coli</jats:italic> isolates and 20.3% of 2,303 <jats:italic>K. pneumoniae</jats:italic> isolates. We then selected 52 <jats:italic>E. coli</jats:italic> isolates and 68 <jats:italic>K. pneumoniae</jats:italic> isolates with a negative ESBL confirmation test, as well as comparable number of isolates with confirmed ESBL-positive tests, and examined them for the presence of TEM, SHV, plasmid-borne <jats:italic>ampC</jats:italic> , and CTX-M genes. We found that 62% of nonconfirming <jats:italic>E. coli</jats:italic> isolates and 75% of nonconfirming <jats:italic>K. pneumoniae</jats:italic> harbored a plasmid-borne AmpC enzyme of the CIT or DHA type. The majority of nonconfirming <jats:italic>E. coli</jats:italic> and <jats:italic>K. pneumoniae</jats:italic> from the Asia-Pacific region harbor important β-lactamases, and a positive screening test alone should be sufficient grounds to report resistance to extended-spectrum cephalosporins in this region. </jats:p>
Umfang: 1478-1482
ISSN: 0095-1137
1098-660X
DOI: 10.1128/jcm.02470-06